WHO ICTRP trial
Triple therapy for primary immune thrombocytopenia
ACTRN12611000015943 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12611000015943 |
|---|---|
| Public title | Triple therapy for primary immune thrombocytopenia |
| Scientific title | Efficacy, safety and tolerability of combination therapy with high dose dexamethasone, low dose rituximab and cyclosporine in patients with primary immune thrombocytopenic purpura (ITP) |
| Primary sponsor | Professor Beng Hock Chong |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Australia |
| Conditions | Primary immune thrombocytopenia; Primary immune thrombocytopenia;Blood - Haematological diseases |
| Interventions | triple therapy: 1. high dose dexamethasone (40mg orally days 1-4) 2. low dose rituximab (fixed 100mg intravenous days 7, 14, 21, 28) 3. cyclosporine (2.5-3mg/kg/day orally in 2 divided doses days 1-28) overall duration of treatment is 1… |
| Registration date | Jun 1, 2011 |
| Target size | 15 |
| Secondary IDs | HREC/10/STG/59 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: